One Blood Test for 50+ Cancers? What the Latest Global Evidence Says

A single blood test designed to detect signals from more than 50 cancers sounds extraordinary. But what can Galleri actually detect, what have large studies found — and could it really change cancer screening?

What the News Is Saying

Galleri is a multi-cancer early detection blood test designed to look for cancer-related signals in the bloodstream. Its developers say the test can identify signals associated with more than 50 types of cancer and can often predict where in the body that signal originated.

That possibility has attracted considerable attention because many cancers still have no established population screening programme. In September 2026, an FDA advisory committee voted 7–2, with one abstention, that the benefits of the proposed test outweighed its risks for the intended use considered by the committee. That vote was not the same as FDA approval.

At the same time, results from the large NHS-Galleri trial in England provided an important counterweight: the trial did not meet its primary endpoint of significantly reducing the number of cancers diagnosed at stages III and IV after three annual rounds of screening.

Peel the Layer

Galleri does not look directly for a tumour. It examines fragments of cell-free DNA circulating in the blood and analyses patterns of DNA methylation — chemical changes that can differ between cancer and non-cancer cells.

Sequencing and machine-learning methods are then used to decide whether a cancer signal appears to be present. When a signal is detected, the test also attempts to predict the part of the body where that signal originated.

This distinction matters. Galleri is a screening test, not a diagnosis. A cancer signal requires further investigation to determine whether cancer is actually present, while a negative result cannot rule out cancer.

Galleri: The Key Numbers

The PATHFINDER 2 study included 35,878 people aged 50 or over in North America. The test's specificity was 99.64%, while its positive predictive value was 60.3%. Among cancer episodes overall, sensitivity was 39.3%.

When a cancer signal was detected, Galleri predicted where in the body the signal originated with 91.3% accuracy. Overall, approximately one cancer was detected for every 185 people screened.

The much larger NHS-Galleri trial involved 142,250 participants aged 50 to 77 in England. Despite its scale, the trial did not meet its primary endpoint of significantly reducing the number of cancers diagnosed at stages III and IV after three annual screening rounds.

Headline vs Evidence

Headline: One blood test could screen for more than 50 cancers.

Evidence: Galleri can detect cancer-associated signals across many cancer types, but its sensitivity varies and it misses many cancers. In PATHFINDER 2, overall episode sensitivity was 39.3%.

The NHS-Galleri trial also did not meet its primary endpoint of significantly reducing cancers diagnosed at stages III and IV after three annual screening rounds. The evidence therefore does not show that one blood test can replace established cancer-screening programmes.

Here's the Catch

A screening test can sound impressive when it detects cancers that might otherwise be difficult to find early. But finding a cancer signal is not the same as proving that screening ultimately saves lives.

False-positive results can lead to further scans, tests and procedures in people who do not have cancer. False-negative results matter too: a negative Galleri result cannot rule out cancer and should not replace established screening or investigation of symptoms.

There is also the question of overdiagnosis — finding cancers that might never have caused illness during a person's lifetime. The crucial long-term question is therefore not simply how many cancers Galleri can detect, but whether using it in population screening improves important health outcomes while keeping unnecessary investigation and harm acceptably low.

The Bigger Health Story

Galleri is part of a much bigger shift in medicine: trying to find disease earlier, often before symptoms appear. Advances in genomics, blood-based biomarkers and artificial intelligence are making it possible to detect biological signals that conventional screening may not look for.

That could be particularly important for cancers for which there is currently no established population screening programme. But earlier detection is valuable only if it leads to better outcomes. Finding more abnormalities does not automatically mean preventing more deaths.

This is why large randomised trials matter. The central question is not simply whether a blood test can detect cancer signals, but whether adding it to existing healthcare ultimately reduces late-stage disease and cancer deaths without causing unacceptable harm through false positives, overdiagnosis and unnecessary investigations.

Published Human Evidence

These individual experiences show what early detection can mean for particular patients, but they cannot establish whether population-wide Galleri screening reduces cancer deaths. That requires evidence from large controlled trials.

What Happens Next?

The Galleri story is not finished. Researchers will continue analysing the NHS-Galleri trial and other studies to understand which cancers the test detects best, which it tends to miss, and what happens to people after a cancer signal is found.

The most important evidence will go beyond detection rates. Researchers need to establish whether multi-cancer screening can reduce late-stage diagnoses and, ultimately, cancer deaths — while also measuring false positives, unnecessary investigations, overdiagnosis and the demands placed on healthcare services.

Regulators will also have to weigh the potential benefits against these uncertainties. An FDA advisory committee's September 2026 vote was an important step in the US regulatory process, but it was not itself FDA approval.

For now, Galleri should not be treated as a replacement for established cancer-screening programmes or for seeking medical advice about concerning symptoms.

Sources & Further Reading

• Nature Medicine — PATHFINDER 2: performance and safety of a multi-cancer early detection test
• Nature Medicine — Randomised NHS-Galleri trial
• US Food and Drug Administration — September 2026 advisory committee meeting
• Oregon Health & Science University — PATHFINDER 2 findings and published patient experiences

Health Note

This article is for general health information and does not replace individual medical advice. A negative multi-cancer blood test cannot rule out cancer. Continue to take part in recommended cancer-screening programmes, and seek medical advice if you develop persistent, unusual or concerning symptoms, regardless of any screening-test result.